SC
MYGN icon

Syon Capital’s Myriad Genetics MYGN Stock Holding History

Syon Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Buy
+22,346
New +$101K 0.01% 936
2025
Q1 		– Sell
-12,856
Closed -$176K – 635
2024
Q4 		$176K Buy
+12,856
New +$237K 0.02% 530

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Syon Capital's MYGN Position: Q2 2026 in Review

Syon Capital opened a new position in Myriad Genetics (MYGN) in Q2 2026: 22,346 shares worth $128K. The stake represents 0.01% of the portfolio and ranks #936 among its holdings. This is a return to the name: Syon Capital previously reported a position in MYGN as recently as Q4 2024.

Syon Capital first reported a position in MYGN in Q4 2024 and has held it in 2 quarters since. The position peaked at $176K in Q4 2024. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Syon Capital held 22,346 shares of Myriad Genetics worth $128K as of Q2 2026.
  • Myriad Genetics was a new Syon Capital position in Q2 2026.
  • Myriad Genetics made up 0.01% of Syon Capital's portfolio in Q2 2026, its #936 holding.
  • Syon Capital first reported a position in Myriad Genetics in Q4 2024 and has held it in 2 quarters since.
  • Syon Capital's Myriad Genetics position peaked at $176K in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.